Different effects of agonistic vs. antagonistic GnRH-analogues (triptorelin vs. cetrorelix) on bone modeling and remodeling in peripubertal female rats

Experimental and Clinical Endocrinology and Diabetes

Volumn 113, Issue 8, 2005, Pages 451-456

  Roth, Christian L ^a   Neu, C ^b   Jarry, H ^c   Schoenau, E ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Bone mineralization; Bone modeling and remodeling; GnRH analogues; Puberty

Indexed keywords

CETRORELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; TRIPTORELIN;

ANIMAL EXPERIMENT; ARTICLE; BONE MINERALIZATION; BONE REMODELING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; DRUG INHIBITION; NONHUMAN; PRIORITY JOURNAL; PUBERTY; RAT;

ANIMALS; BONE REMODELING; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; LUTEOLYTIC AGENTS; PUBERTY, PRECOCIOUS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GONADOTROPIN; SEXUAL MATURATION; TRIPTORELIN;

EID: 25444529722     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865710     Document Type: Article

References (39)

1. Bakalov VK, Axelrod L, Baron J, Hanton L, Nelson LM, Reynolds JC, Hill S, Troendle J, Bondy CA. Selective reduction in cortical bone mineral density in Turner syndrome independent of ovarian hormone deficiency. J Clin Endocrinol Metab 2003; 88: 5717-5722
2. Bertelloni S, Baroncelli GI, Ferdeghini M, Menchini-Fabris F, Saggese G. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur J Pediatr 2000; 159: 369-374
3. Comaru-Schally AM, Brannan W, Schally AV, Colcolough M, Monga M. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 1998; 83: 3826-3831
4. Crowley WF Jr, Comite F, Vale W, Rivier J, Loriaux DL, Cutler GB Jr. Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 1981; 52: 370-372
5. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83: 1561-1566
6. Frost HM, Schoenau E. The "muscle-bone unit" in children and adolescents: a 2000 overview. J Pediatr Endocrinol Metab 2000; 13: 571-590
7. Griesinger G, Felberbaum RE, Schultze-Mosgau A, Diedrich K. Gonadotropin-releasing hormone antagonists for assisted reproductive techniques: are there clinical differences between agents? Drugs 2004; 64: 563-575
8. Grumbach MM. Estrogen, bone, growth and sex: a sea change in conventional wisdom. J Pediatr Endocrinol Metab 2000; 13 (Suppl 6): 1439-1455
9. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999; 84: 4583-4590
10. Horvath JE, Toller GL, Schally AV, Bajo AM, Groot K. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. Proc Natl Acad Sci USA 2004; 101: 4996-5001
11. Järvinen TL, Kannus P, Pajamaki I, Vuohelainen T, Tuukkanen J, Järvinen M, Sievanen H. Estrogen deposits extra mineral into bones of female rats in puberty, but simultaneously seems to suppress the responsiveness of female skeleton to mechanical loading. Bone 2003; 32: 642-651
12. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 2004; 145: 1996-2005
13. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001; 86: 4711-4716
14. Lotinun S, Westerlind KC, Kennedy AM, Turner RT. Comparative effects of long-term continuous release of 16 alpha-hydroxyestrone and 17 beta-estradiol on bone, uterus, and serum cholesterol in ovariectomized adult rats. Bone 2003; 33: 124-131
15. Mul D, Oostdijk W, Otten BJ, Rouwe C, Jansen M, Delemarre-Van de Waal HA, Waelkens JJ, Drop SL. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience. J Pediatr Endocrinol Metab 2000; 13 (Suppl 1): 765-772
16. Mul D, Bertelloni S, Carel JC, Saggese G, Chaussain JL, Oostdijk W. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm Res 2002; 58: 1-7
17. Ojeda SR, Urbanski HF. Puberty in the rat: In: The Physiology of Reproduction. 2nd ed. New York: Raven Press Ltd., 1994: 377-379
18. Oostdijk W, Drop SL, Odink RJ, Hummelink R, Partsch CJ, Sippell WG. Long-term results with a slow-release gonadotropin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group. Acta Paediatr Scand 1991; 372 (Suppl): 39-45
19. Ott SM. Attainment of peak bone mass. J Clin Endocrinol Metab 1990; 71: 1082 A-1082 C
20. Paoletti AM, Serra GG, Cagnacci A, Vacca AM, Guerriero S, Solla E, Melis GB. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril 1996; 65: 707-710
21. Partsch CJ, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol (Oxf) 2002; 56: 129-148
22. Rakover Y, Lu P, Briody JN, Tao C, Weiner E, Ederveen AG, Cowell CT, Ben-Shlomo I. Effects of delaying puberty on bone mineralization in female rats. Hum Reprod 2000; 15: 1457-1461
23. Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 1995; 10: 1974-1981
24. Reissmann T, Schally AV, Bouchard P, Riethmiiller H, Engel J. The LHRH antagonist cetrorelix: a review. Hum Reprod Update 2000; 6: 322-331
25. Roth C, Leonhardt S, Seidel C, Luft H, Wuttke W, Jarry H. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model. Pediatr Res 2000; 48: 468-474
26. Roth C, Schricker M, Lakomek M, Strege A, Heiden I, Luft H, Munzel U, Wuttke W, Jarry H. Autoregulation of the GnRH system during puberty: effects of antagonistic versus agonistic GnRH analogues in a female rat model. J Endocrinol 2001; 169: 361-371
27. Roth C. Therapeutic potential of GnRH antagonists in the treatment of precocious puberty. Expert Opin Investig Drugs 2002; 11: 1253-1259
28. Roth C, Hegemann F, Hildebrandt J, Balzer I, Witt A, Wuttke W, Jarry H. Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models. Pediatr Res 2004; 55: 126-133
29. Saggese G, Bertelloni S, Baroncelli GI, Battini R, Franchi G. Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty. Eur J Pediatr 1993; 152: 717-720
30. Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003; 4: CD001297
31. Schoenau E, Saggese G, Peter F, Baroncelli GI, Shaw NJ, Crabtree NJ, Zadik Z, Neu CM, Noordam C, Radetti G, Hochberg Z. From bone biology to bone analysis. Horm Res 2004; 61: 257-269
32. Seeman E. Invited review: Pathogenesis of osteoporosis. J Appl Physiol 2003; 95: 2142-2151
33. Theintz G, Buchs B, Rizzoli R, Slosman D, Clavien H, Sizonenko PC, Bonjour JP. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 1992; 75: 1060-1065
34. Urbanski HF, Ojeda SR. In vitro simulation of prepubertal changes in pulsatile luteinizing hormone release enhances progesterone and 17 beta-estradiol secretion from immature rat ovaries. Endocrinology 1985; 117: 638-643
35. van der Eerden BC, Karperien M, Wit JM. The estrogen receptor in the growth plate: implications for pubertal growth. J Pediatr Endocrinol Metab 2001; 14(Suppl 6): 1527-1533
36. Wang L, McMahan CA, Banu J, Okafor MC, Kalu DN. Rodent model for investigating the effects of estrogen on bone and muscle relationship during growth. Calcif Tissue Int 2003; 72: 151-155
37. Wildt L, Marshall G, Knobil E. Experimental induction of puberty in the infantile female rhesus monkey. Science 1980; 207: 1373-1375
38. Yanovski JA, Rose SR, Municchi G, Pescovitz OH, Hill SC, Cassorla FG, Cutler GB Jr. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003; 348: 908-917
39. Zapatero-Caballero H, Sanchez-Franco F, Fernandez-Mendez C, Garcia-San Frutos M, Botella-Cubells LM, Fernandez-Vazquez G. Gonadotropin-releasing hormone receptor gene expression during pubertal development of female rats. Biol Reprod 2004; 70: 348-355